ALX Oncology Holdings Inc. (ALXO) Revenue History
Annual and quarterly revenue from 2018 to present
ALXO Revenue Over Time (2018–2025)
ALXO Revenue Growth History
1 of 3 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- +132.0%
- FY2020 revenue growth
- -75.4%
- FY2021 revenue growth
- -100.0%
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
ALXO Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 24, 2026, ALX Oncology Holdings Inc. (ALXO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
ALXO's historical revenue data shows various trends over time. ALX Oncology Holdings Inc.'s highest annual revenue of $4.8 million was recorded in 2019.
Peer Comparison
Compared to Healthcare sector peers — including FATE (-52.6% YoY), RCUS (+67.4% YoY), and AGEN (+24.5% YoY). Compare ALXO vs FATE →
ALXO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALXOCurrent | $0 | - | - | - | |
 FATE | $7M | -52.6% | -26.7% | -2222.4% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% |
ALXO Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-104,021,000 | - |
| 2024 | $0 | - | $0 | - | $-142,467,000 | - |
| 2023 | $0 | - | $0 | - | $-170,278,000 | - |
| 2022 | $0 | - | $0 | - | $-127,436,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-83,555,000 | - |
| 2020 | $1.2M | -75.4% | $107K | 9.1% | $-43,663,000 | -3694.0% |
| 2019 | $4.8M | +132.0% | $436K | 9.1% | $-19,183,000 | -400.0% |
| 2018 | $2.1M | - | $187K | 9.0% | $-13,684,000 | -662.0% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALXO — Frequently Asked Questions
Quick answers to the most common questions about buying ALXO stock.
Is ALXO's revenue growth accelerating or slowing?
ALXO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ALXO's revenue history from 2018 to 2026?
ALX Oncology Holdings Inc. (ALXO) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ALXO's long-term revenue growth rate (CAGR)?
ALX Oncology Holdings Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ALXO.
Why does ALXO's quarterly revenue fluctuate?
ALXO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. ALX Oncology Holdings Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is ALXO's revenue distributed by segment?
ALXO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ALXO's revenue compare to industry peers?
ALX Oncology Holdings Inc. (ALXO) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.